Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMPHNYSE:ANWNASDAQ:ORPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$24.47+1.1%$25.20$22.64▼$53.96$1.16B0.78480,046 shs548,566 shsANWAegean Marine Petroleum Network$0.00$0.60▼$5.10$26.64M3.27526,099 shsN/AORPHOrphazyme A/S$1.43$0.51▼$77.77$30.72M1.681.37 million shs941,400 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals+0.17%-0.49%+1.13%-22.63%-44.32%ORPHOrphazyme A/S0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMPHAmphastar Pharmaceuticals4.2359 of 5 stars3.11.00.03.73.64.21.3ANWAegean Marine Petroleum NetworkN/AN/AN/AN/AN/AN/AN/AN/AORPHOrphazyme A/SN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPHAmphastar Pharmaceuticals 2.25Hold$32.3332.13% UpsideANWAegean Marine Petroleum Network 0.00N/AN/AN/AORPHOrphazyme A/S 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PHE, ORPH, AMPH, and ANW Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025AMPHAmphastar PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$45.00 ➝ $30.005/8/2025AMPHAmphastar PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $35.004/10/2025AMPHAmphastar PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold3/21/2025AMPHAmphastar PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$36.00 ➝ $32.00(Data available from 5/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPHAmphastar Pharmaceuticals$730.66M1.59$3.41 per share7.17$13.35 per share1.83ANWAegean Marine Petroleum Network$5.67B0.00N/AN/A$14.96 per share0.00ORPHOrphazyme A/SN/AN/AN/AN/A$2.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPHAmphastar Pharmaceuticals$137.54M$2.768.167.442.1921.80%26.44%11.89%8/6/2025 (Estimated)ANWAegean Marine Petroleum Network-$29.30M-$0.53N/A0.00N/AN/AN/AN/AN/AORPHOrphazyme A/S-$97.01MN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/AANWAegean Marine Petroleum Network$0.034.58%N/AN/A N/AORPHOrphazyme A/SN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPHAmphastar Pharmaceuticals0.823.432.61ANWAegean Marine Petroleum NetworkN/AN/AN/AORPHOrphazyme A/S0.141.80N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPHAmphastar Pharmaceuticals65.09%ANWAegean Marine Petroleum Network34.60%ORPHOrphazyme A/S10.74%Insider OwnershipCompanyInsider OwnershipAMPHAmphastar Pharmaceuticals27.50%ANWAegean Marine Petroleum NetworkN/AORPHOrphazyme A/SN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPHAmphastar Pharmaceuticals1,62047.50 million35.05 millionOptionableANWAegean Marine Petroleum NetworkN/A40.64 millionN/AOptionableORPHOrphazyme A/S14135.31 millionN/ANot OptionablePHE, ORPH, AMPH, and ANW HeadlinesRecent News About These CompaniesHow Four Sigmatic Made Mushrooms A Multi-Billion Dollar CategoryNovember 11, 2024 | forbes.comWeight loss care is leading IPO-hopeful Omada Health's latest growth surge as Ozempic boom continuesOctober 30, 2024 | businessinsider.comIncyte’s Strong Financial Performance and Promising Pipeline Lead to Buy RatingOctober 30, 2024 | markets.businessinsider.comOzempic could help reduce Alzheimer’s risk for some, study suggests: ‘Shifting the paradigm’October 26, 2024 | msn.comAquestive Therapeutics’ Favorable OAS Study Boosts Anaphylm’s Prospects with Raised Price Target and Buy RatingOctober 25, 2024 | markets.businessinsider.comOzempic linked to lower risk of Alzheimer’s diagnosis in observational studyOctober 24, 2024 | statnews.comPharmalittle: We’re reading about drug shortages, what drugmakers didn’t tell Alzheimer’s trial patients and moreOctober 24, 2024 | statnews.comNovo’s Ozempic Linked to Reduced Alzheimer’s DiagnosesOctober 24, 2024 | msn.comHow Europe's Biggest Buyout Deal Descended Into a Bruising BrawlOctober 24, 2024 | bloomberg.comNasdaq Welcomes Strategic Partners A/S to Nasdaq Copenhagen Main MarketOctober 24, 2024 | finanznachrichten.deUK regulator approves second Alzheimer's drug in months but government won't pay for itOctober 23, 2024 | abcnews.go.comFDA Approves Pfizer's Respiratory Syncytial Virus Vaccine Abrysvo For Adults Below 60 YearsOctober 23, 2024 | benzinga.comFDA approves Pfizer's RSV shot Abrysvo for all at-risk adultsOctober 23, 2024 | fiercepharma.comArtiphon’s new Orba instrument can sample sounds liveOctober 22, 2024 | techcrunch.comInjectable drug to ease advanced Parkinson's disease symptoms approved by FDAOctober 17, 2024 | msn.com3rd time's the charm: AbbVie scores FDA nod for continuous Parkinson's disease therapy VyalevOctober 17, 2024 | fiercepharma.comUS FDA expands approval for Avadel's sleep disorder drugOctober 17, 2024 | msn.comJ&J Scraps Pipeline Assets Including Alzheimer’s and Parkinson’s CandidatesOctober 17, 2024 | biospace.comTop six European biotech entrepreneurs to know in 2024 (according to VCs)October 17, 2024 | labiotech.euFDA Approves Pfizer's HYMPAVZI For Hemophilia A And B Treatment In Adults And AdolescentsOctober 12, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePHE, ORPH, AMPH, and ANW Company DescriptionsAmphastar Pharmaceuticals NASDAQ:AMPH$24.47 +0.27 (+1.12%) Closing price 04:00 PM EasternExtended Trading$24.09 -0.38 (-1.54%) As of 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Aegean Marine Petroleum Network NYSE:ANWAegean Marine Petroleum Network Inc., together with its subsidiaries, operates as a marine fuel logistics company that markets and supplies refined marine fuel and lubricants to vessels in port, at sea, and on rivers worldwide. The company offers fueling services to ocean-going and a range of coastal vessels, including oil tankers, container ships, drybulk carriers, cruise ships, reefers, LNG/LPG carriers, car carriers, and ferries, as well as to marine fuel traders, brokers, and other end-users of marine fuel and lubricants. It also markets and distributes marine lubricants under the Alfa Marine Lubricants brand; and provides a range of shipping services, such as technical support and maintenance, insurance arrangement and handling, financial administration, and accounting services. As of December 31, 2016, the company owned and operated a fleet of 46 bunkering vessels, including 45 double hulls and 1 single hull special purpose vehicle; 15 double hull bunkering vessels with an aggregate carrying capacity of approximately 292,400 deadweight ton (dwt); operated 10 land-based storage facilities with an aggregate storage capacity of approximately 1,075,000 cubic meters; and operated 2 vessels as floating storage facility with a cargo carrying capacity of approximately 86,800 dwt. Aegean Marine Petroleum Network Inc. was founded in 1995 and is headquartered in Athens, Greece.Orphazyme A/S NASDAQ:ORPHOrphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
